J Korean Oncol Nurs.  2011 Feb;11(1):26-32.

Literature Review of Cognitive Developmental Interventions on Patients with Breast Cancer undergoing Chemotherapy

• Choi EH
• Chung BY
• Kim GD
• Kim KH
• Byun HS

Abstract

PURPOSE
The purpose of this study was to analyze the trend of cognitive developmental interventions on patients with breast cancer who underwent chemotherapy.
METHODS
The researcher searched databases and selected 17 literatures using chemotherapy, breast cancer, cognitive function and intervention as searching key words. Searched databases included Ovid, Pubmed, Proquest and Medline and data collection period was from January 2000 to May 2010.
RESULTS
Interventions for patients with breast cancer have been continuously developed and frequent research topics included breast cancer, chemotherapy, quality of life, and cognitive function. In terms of study design, four research articles were pre-experimental study designs, one was case study, and the rest of studies were nonequivalent pretest-posttest control group design. Effects of intervention were examined in only 5 studies among 17. The interventions were not found to have direct effects in cognitive improvement.
CONCLUSION
It is needed to figure out the mechanism of cognitive deterioration of the patients with breast cancer who underwent chemotherapy. And nursing interventions needs to be developed in order to hold up the cognitive downhill and help their cognitive rehabilitation.

Keyword

Drug therapy; Breast neoplasms; Cognition; Intervention studies

MeSH Terms

Breast
Breast Neoplasms
Cognition
Data Collection
Humans
Clinical Trial
Quality of Life

Reference

1. Kang JJ. Effects of cognitive function enhancement program: focusing on working memory [master]. 2008. Seoul: Seoul National University.

2. Downie FP, Mar Fan HG, Houede-tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006. 15:921–930.

3. Vardy J, Wefel JS, Ahles T, Tannock IF, Schange SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008. 19:623–629.

4. Bender CM, Pacella BA, Sereika SM, Brufsky AM, Vogel VG, Rastogi P, et al. What do perceived Cognitive Problems Reflect? J Support Oncol. 2008. 6:238–242.

5. O'Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer. 2002. 3:S116–S120.

6. Schilder CM, Eggens PC, Seynavev C, Linn SC, Gundy CM, Beex LV, et al. Neuropsychological functioning in postmeno: cross-sectional findings from the neuropsychological TEAM-side study. Pausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy. Acta Oncol. 2009. 48:76–85.

7. Biegler KA, Chaoul MA, Cohen L. Cancer, cognitive impairment, and meditation. Acta Oncol. 2009. 48:18–26.

8. Vetto IP, Vetto JT, Cognitive Dysfunction. An educational needs area improved by a single intervention. J Cancer Educ. 2007. 22:197–201.

9. Freeman JR, Broshek DK. Assessing cognitive dysfunction in breast cancer: what are the tools? Clin Breast Cancer. 2002. 3:S91–S99.

10. Jenkins V, Shilling V, Fallowfield , Howell A, hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology. 2004. 13:61–66.

11. Mulrooney T. Cognitive impairment after breast Cancer treatment. Clin J Oncol Nurs. 2008. 12:678–680.

12. Ferguson RJ, Ahles TA, Saykin AJ, McDonald BC, Furstcnberg CT, Cole BF, et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology. 2007. 16:772–777.

13. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009. 115:1776–1783.

14. Bell M, Bryson G, Wexler BE. Cognitive remediation of working memory deficits: durability of training effects in severely impaired and less severely impaired schizophrenia. Acta Psychiatr Scand. 2003. 108:101–109.

15. Cahn-Weiner AD, Malloy FP, Rebok WG, Ott RB. Results of a randomized placebo-controlled study of memory training for mildly impaired Alzheimer's disease patients. Appl Neuropsychol. 2003. 10:215–223.

16. Gorman P, Dayle R, Hood CA, Rumrell L. Effectiveness of the ISAAC cognitive prosthetic system for improving rehabilitation outcomes with neurofunctional impairment. NeuroRehabilitation. 2003. 18:57–67.

17. Edelman S, Bell DR, Kidman AD. A group cognitive behaviour therapy programme with metastatic breast cancer patients. Psychooncology. 1999. 8:295–305.

18. Si JY. The effects of chronic schizophrenia patients??symptoms and cognitive functions on their social functions [master]. 2009. Gyeongbuk: Catholic University of Daegu.

19. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in women with breast cancer. Psychooncology. 2006. 15:422–430.

20. Marino P, Roche H, Biron P, Janvier M, Spaeth D, Fabbro M, et al. Deterioration of quality of life high-risk breast cancer patients treated with high-dose chemotherapy: the PEGASE 01 quality of life study. Value Health. 2008. 11:709–718.

21. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia effects on quality of life among women with breast cancer: a literature review. Psychooncology. 2008. 17:317–328.

22. Jansen SJ, Otten W, van de Velde CJ, Nortier JW, Stiggelbout AM. The impact of the percetption of treatment choice on satisfaction with treatment, experienced chemotherapy burden and current quality of life. Br J Cancer. 2004. 91:56–61.